Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï ȯÀÚ¿¡¼­ Tamoxifen Ä¡·á¿¡ ÀÇÇÑ À¯¹æÃÔ¿µ¼ú»óÀÇ º¯È­ Mammographic Changes in Breast Cancer Patients Treated with Tamoxifen

´ëÇѹæ»ç¼±ÀÇÇÐȸÁö 1997³â 37±Ç 3È£ p.555 ~ 559
±èÀç±Ù, ÀÌÈñ´ë, ±èÁؽÄ, ±èÅÂÈÆ,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀç±Ù (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Áø´Ü¹æ»ç¼±°úÇб³½Ç

ÀÌÈñ´ë (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÀϹݿܰúÇб³½Ç
±èÁؽĠ(  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Áø´Ü¹æ»ç¼±°úÇб³½Ç
±èÅÂÈÆ (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Áø´Ü¹æ»ç¼±°úÇб³½Ç

Abstract

¸ñ Àû : À¯¹æ¾Ï ȯÀÚ¿¡¼­ ¼ö¼úÈÄ À¯¹æ¾ÏÀÇ ¿¹¹æ ¹× Àç¹ß ¾ïÁ¦ ¸ñÀûÀ¸·Î »ç¿ëÇÑ tamoxifen
ÀÌ À¯¹æ½ÇÁúÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â È¿°ú°¡ ÀÖ´ÂÁö ÆÇÁ¤Çϱâ À§ÇÏ¿© À¯¹æÃÔ¿µ¼ú»ó À¯¹æ½ÇÁúÀÇ
º¯È­¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : À¯¹æ¾Ï ȯÀÚ·Î ¼ö¼úÈÄ Áö¼ÓÀûÀ¸·Î ÀÏÀÏ 20mg tamoxifenÀ» »ç¿ëÇÑ À¯¹æ¾Ï
ȯÀÚ±º 20¸í (¿¡½ºÆ®·ÎÁ¨ ¼ö¿ëü ¾ç¼º 18¿¹ ), È­Çпä¹ý°ú tamoxifenÀ» º´ÇàÇÑ È¯ÀÚ±º 20¸í
(¿¡½ºÆ®·ÎÁ¨ ¼ö¿ëü ¾ç¼º 17¿¹ ), ±×¸®°í À¯¹æ¾Ï¼ö¼ú ÈÄ È­Çпä¹ý¸¸ ½ÃÇàÇÑ È¯ÀÚ±º°ú Á¤»ó
´ëÁ¶±ºÀ¸·Î µ¿ÀÏÇÑ ¿¬·ÉÀÇ Á¤»ó¿©¼º °¢°¢ 20¸íÀ» ´ë»óÀ¸·Î 4±ºÀ¸·Î ºÐ·ù ÇÏ¿´´Ù.
¹æ»ç¼±°ú ÀÇ»ç 2¸íÀÌ À¯¹æ¾Ï ȯÀÚ¿¡¼­´Â ¼ö¼ú ¹Ý´ëÃø À¯¹æÀ», Á¤»ó´ëÁ¶±º¿¡¼­´Â ¿ÞÂÊ À¯¹æ
ÀÇ ÃßÀûÀ¯¹æÃÔ¿µ»óÀ» ºñ±³ÇÏ¿© À¯¹æ½ÇÁúÀÇ ¸éÀû¹üÀ§, ±×¸®°í ÄíÆÛ¾¾Àδë(Cooper's ligament)
¿Í À¯µµ°üÀÇ °¡½ÃÈ­ Á¤µµ¿¡ µû¶ó À¯¹æ½ÇÁúÀÇ º¯È­¸¦ ÆÇÁ¤ÇÏ¿´´Ù.
°á °ú : À¯¹æ¾Ï ¼ö¼úÈÄ tamoxifen¸¸À» »ç¿ëÇÑ ±º°ú tamoxifen°ú È­Çпä¹ýÀ» º´ÇàÇÑ ±º¿¡¼­
´Â tamoxifen »ç¿ëÀü°ú ºñ±³ÇÏ¿© ÀÏÁ¤ ±â°£ÀÇ ÃßÀû°Ë»ç»ó °¢°¢ 15¸í (75%), 14¸í (70%)¿¡
¼­ À¯¹æ ½ÇÁúÀÌ °¨¼ÒÇÏ¿´´Ù. À¯¹æ¾Ï ¼ö¼ú ÈÄ È­ÇÐ ¿ä¹ý¸¸À» ½ÃÇàÇÑ ±ºÀÇ 17¸í (85%), Á¤»ó
´ëÁ¶±ºÀÇ 18¸í (90%)¿¡¼­´Â ÃßÀûÀ¯¹æÃÔ¿µ¼ú»ó À¯¹æ½ÇÁú¿¡ ÀüÇô º¯È­°¡ ¾ø¾ú´Ù.
°á ·Ð : À¯¹æ¾Ï ¼ö¼úÀ» ¹ÞÀº ȯÀÚ¿¡¼­ À¯¹æ¾ÏÀÇ Àç¹ß°ú À¯¹æ½ÇÁúÀÇ Áõ½ÄÀ» ¾ïÁ¦Çϱâ À§ÇÏ
¿© »ç¿ëÇÑ tamoxifenÀº À¯¹æÃÔ¿µ¼ú»ó À¯ÀÇÇÏ°Ô À¯¹æ½ÇÁúÀ» °¨¼Ò½ÃÅ°¸ç, À¯¹æÃÔ¿µ¼úÀº
tamoxifenÀÇ È¿°ú¸¦ °´°üÀûÀ¸·Î ÆÇÁ¤ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ¸·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
Purpose : To evaluate the efficacy of tamoxifen, as shown by mammographic changes.
Materials and Methods : We studied the mammograms of 20 breast cancer patients
treated with tamoxifen(20mg/day) and 20 patients treated with tamoxifen(20mg/day) in
combination with chemothrapy. Control groups consisted of 20 breast cancer patients
treated with chemotherapy and 20 healthy women ; the patterns pf age distribution and
menstrual cycle among these participants were similar to these of the study groups.
Two radiologists determined parenchymal changes as seen on follow-up mammogram, of
the contralateral breast in patients with breast cancer, and of the left breast in healthy
women.
Results : Follow-up mammogram showed decreased breast parenchyma in 75% of
patients treated with tamoxifen, and in 70% of patients treated with tamoxifen and
chemotherapy. Mammographic changes were not noted in 85% of patients treated with
chemotherapy and in 90% of healthy women.
Conclusion : On follow-up mammogram, breast parenchyma was seen to have been
decreased by tamoxifen, used to prevent the recurrence of breast cancer and for its
antiproliferative effect. Mammography might be a suitable method for determining the
effect of tamoxifen.

Å°¿öµå

Breast radiography; Breast neoplasms; therapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS